Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility in Bengaluru.
This new capability will complement its commercial payload, linker, and monoclonal antibodies services, enabling Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
Syngene will be among a handful of CDMOs with full-service capabilities.
For more information, contact +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT.
Author's summary: Syngene International expands ADC capabilities.